The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Daniel J. Drucker

Mt. Sinai Hospital

600 University Avenue TCP5-1004

Toronto Ontario

Canada M5G 1X5


Name/email consistency: high



  • Mt. Sinai Hospital, 600 University Avenue TCP5-1004, Toronto Ontario, Canada M5G 1X5. 2011 - 2012
  • Samuel Lunenfeld Research Institute, Department of Medicine, Mount Sinai Hospital, 600 University Avenue TCP5-1004. 2006 - 2011
  • Banting and Best Diabetes Centre, University of Toronto, Toronto General Hospital, 200 Elizabeth St. 2004 - 2007
  • Department of Medicine, Banting and Best Diabetes Centre, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Canada. 2007
  • Department of Medicine, Toronto General Hospital, Banting and Best Diabetes Centre, University of Toronto. 2000 - 2006
  • Banting and Best Diabetes Centre, Toronto, Ontario, Canada. 2005
  • Department of Medicine, Toronto Hospital, University of Toronto, Ontario. 1997 - 2003


  1. Intestinotrophic Glucagon-Like Peptide-2 (GLP-2) Activates Intestinal Gene Expression and Growth Factor-Dependent Pathways Independent of the Vasoactive Intestinal Peptide Gene in Mice. Yusta, B., Holland, D., Waschek, J.A., Drucker, D.J. Endocrinology (2012) [Pubmed]
  2. Disruption of the murine glp2r impairs paneth cell function and increases susceptibility to small bowel enteritis. Lee, S.J., Lee, J., Li, K.K., Holland, D., Maughan, H., Guttman, D.S., Yusta, B., Drucker, D.J. Endocrinology (2012) [Pubmed]
  3. Cardiovascular biology of the incretin system. Ussher, J.R., Drucker, D.J. Endocr. Rev. (2012) [Pubmed]
  4. The safety of incretin-based therapies--review of the scientific evidence. Drucker, D.J., Sherman, S.I., Bergenstal, R.M., Buse, J.B. J. Clin. Endocrinol. Metab. (2011) [Pubmed]
  5. Glucagon-Like Peptide-1 Receptor Activation Inhibits Growth and Augments Apoptosis in Murine CT26 Colon Cancer Cells. Koehler, J.A., Kain, T., Drucker, D.J. Endocrinology (2011) [Pubmed]
  6. Liraglutide. Drucker, D.J., Dritselis, A., Kirkpatrick, P. Nat. Rev. Drug. Discov (2010) [Pubmed]
  7. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Drucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S., Buse, J.B. Diabetes. Care (2010) [Pubmed]
  8. The role of gut hormones in glucose homeostasis. Drucker, D.J. J. Clin. Invest. (2007) [Pubmed]
  9. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Drucker, D.J. Diabetes. Care (2007) [Pubmed]
  10. The biology of incretin hormones. Drucker, D.J. Cell Metab. (2006) [Pubmed]
  11. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker, D.J., Nauck, M.A. Lancet (2006) [Pubmed]
  12. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Drucker, D.J. Nature Clinical Practice. Endocrinology & Metabolism (2005) [Pubmed]
  13. Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?. Drucker, D.J. Nature Clinical Practice. Endocrinology & Metabolism (2005) [Pubmed]
  14. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Baggio, L.L., Kim, J.G., Drucker, D.J. Diabetes (2004) [Pubmed]
  15. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Drucker, D.J. Expert. Opin. Investig. Drugs (2003) [Pubmed]
  16. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Drucker, D.J. Mol. Endocrinol. (2003) [Pubmed]
  17. Enhancing incretin action for the treatment of type 2 diabetes. Drucker, D.J. Diabetes. Care (2003) [Pubmed]
  18. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Drucker, D.J. Endocrinology (2003) [Pubmed]
  19. Biological actions and therapeutic potential of the glucagon-like peptides. Drucker, D.J. Gastroenterology (2002) [Pubmed]
  20. Gut adaptation and the glucagon-like peptides. Drucker, D.J. Gut (2002) [Pubmed]
  21. Minireview: the glucagon-like peptides. Drucker, D.J. Endocrinology (2001) [Pubmed]
  22. Glucagon-like peptide 2. Drucker, D.J. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  23. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Drucker, D.J. Curr. Pharm. Des. (2001) [Pubmed]
  24. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2. Drucker, D.J., Lovshin, J., Baggio, L., Nian, M., Adatia, F., Boushey, R.P., Liu, Y., Saleh, J., Yusta, B., Scrocchi, L. Ann. N. Y. Acad. Sci. (2000) [Pubmed]
  25. Glucagon-like peptides. Drucker, D.J. Diabetes (1998) [Pubmed]
  26. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Drucker, D.J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., DeForest, L., Cooper, S., Brubaker, P.L. Nat. Biotechnol. (1997) [Pubmed]
WikiGenes - Universities